QR-010
Showing 1 - 25 of 148
Advanced NSCLC Trial in Shanghai (GLS-012+GLS-010, GLS-012+GLS-010+pemetrexed+carboplatin,
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- GLS-012+GLS-010
- +2 more
-
Shanghai, Shanghai, ChinaShang Hai Pulmonary Hospital
Aug 3, 2023
Pain Trial (GoodFOR Pain, Icy Hot, Tiger Balm)
Not yet recruiting
- Pain
- GoodFOR Pain
- +7 more
- (no location specified)
Jun 6, 2022
Locally Advanced Pancreatic Cancer Trial (Stereotactic body radiation(SBRT), Zimberelimab (GLS-010))
Not yet recruiting
- Locally Advanced Pancreatic Cancer
- Stereotactic body radiation(SBRT)
- Zimberelimab (GLS-010)
- (no location specified)
Aug 22, 2023
Malignant Tumors Trial (IMMH-010)
Enrolling by invitation
- Malignant Neoplasms
-
Guangzhou, ChinaGuangdong Provincial People's Hospital
Dec 30, 2022
Multiple Myeloma Trial in Zhengzhou, Wuhan, Xi'an (Selinexor (80mg/d), Selinexor (100mg/d), Pegylated liposomal doxorubicin)
Recruiting
- Multiple Myeloma
- Selinexor (80mg/d)
- +4 more
-
Zhengzhou, Henan, China
- +4 more
Aug 16, 2022
Classical Hodgkin Lymphoma Trial in Guangzhou (Zimberelimab 240mg)
Recruiting
- Classical Hodgkin Lymphoma
- Zimberelimab 240mg
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Ce
Jun 15, 2023
CNS Lymphoma Trial in China (Selinexor, Rituximab, Methotrexate)
Not yet recruiting
- Central Nervous System Lymphoma
- Selinexor
- +2 more
-
Hefei, Anhui, China
- +4 more
Jan 26, 2023
Type 1 Diabetes Trial in Edmonton (Islet isolation using BMX-010)
Completed
- Type 1 Diabetes
- Islet isolation using BMX-010
-
Edmonton, Alberta, CanadaUniversity of Alberta
May 5, 2022
Persistent, Recurrent, or Metastatic Cervical Cancer Trial in Shanghai (GLS-010, Placebo, paclitaxel)
Not yet recruiting
- Persistent, Recurrent, or Metastatic Cervical Cancer
- GLS-010
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Hospital
Apr 4, 2023
Head Neck Cancer, Quality of Life, Pain Trial in Kaohsiung (Hydrogen Inhalation, Ordinary Air Inhalation)
Recruiting
- Head and Neck Cancer
- +4 more
- Hydrogen Inhalation
- Ordinary Air Inhalation
-
Kaohsiung, TaiwanKaohsiung Medical University Chung-Ho Memorial Hospital
Feb 10, 2023
Metastatic Solid Tumor Cancer Trial in Caen, Paris, Villejuif (Dose escalation, first-in-human phase I clinical trial with an
Recruiting
- Metastatic Solid Tumor Cancer
- Dose escalation, first-in-human phase I clinical trial with an Expansion phase
-
Caen, France
- +2 more
Oct 11, 2022
Stargardt Disease Trial in Miami, McAllen (Gene Therapy-vMCO-010)
Active, not recruiting
- Stargardt Disease
- Gene Therapy-vMCO-010
-
Miami, Florida
- +1 more
Nov 28, 2022
Secondary Progressive Multiple Sclerosis (SPMS) Trial in Tel Aviv (SCM-010)
Not yet recruiting
- Secondary Progressive Multiple Sclerosis (SPMS)
- SCM-010
-
Tel Aviv, IsraelTel Aviv Medical Center
Oct 26, 2022
Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in China (ATG-010 and ATG-008)
Recruiting
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- ATG-010 and ATG-008
-
Chongqing, Chongqing, China
- +5 more
Sep 2, 2022
Idiopathic Hypersomnia, Excessive Daytime Sleepiness Trial in United States (pitolisant)
Enrolling by invitation
- Idiopathic Hypersomnia
- Excessive Daytime Sleepiness
-
Peoria, Arizona
- +57 more
Nov 10, 2022
Retinitis Pigmentosa, Retinitis, Retinal Diseases Trial in Puerto Rico, United States (Gene Therapy Product-vMCO-010, Sham
Active, not recruiting
- Retinitis Pigmentosa
- +6 more
- Gene Therapy Product-vMCO-010
- Sham Injection
-
Beverly Hills, California
- +6 more
Jul 13, 2022
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,
Recruiting
- Lymphoma, Non-Hodgkin
- +6 more
- CB-010
- +2 more
-
Scottsdale, Arizona
- +7 more
Aug 19, 2022
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Canada, France, United States (QR-421a, Sham-procedure (dose
Completed
- Retinitis Pigmentosa
- +7 more
- QR-421a
- Sham-procedure (dose cohort 1&2 only)
-
Boston, Massachusetts
- +6 more
Apr 19, 2022
Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))
Recruiting
- Relapsed or Refractory Multiple Myeloma
- SVd (Selinexor+Bortezomib+dexamethasone)
- Vd (Bortezomib+dexamethasone)
-
Hefei, Anhui, China
- +33 more
Aug 14, 2022
Retinitis Pigmentosa, Usher Syndrome Type 2 Trial in Canada, France, United States (RNA antisense oligonucleotide for
Terminated
- Retinitis Pigmentosa
- Usher Syndrome Type 2
- RNA antisense oligonucleotide for intravitreal injection
-
Boston, Massachusetts
- +6 more
Dec 12, 2022
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Dallas, Madison, London (QR-421a, Sham-procedure)
Active, not recruiting
- Retinitis Pigmentosa
- +7 more
- QR-421a
- Sham-procedure
-
Dallas, Texas
- +2 more
Apr 21, 2022
Musculoskeletal Diseases or Conditions Trial (Educational Tool)
Not yet recruiting
- Musculoskeletal Diseases or Conditions
- Educational Tool
- (no location specified)
Jun 19, 2023